XFC: Who's in Control? Custom Case Solution & Analysis

Evidence Brief: XFC Case Analysis

Financial Metrics

  • Fuji Xerox (FX) revenue growth consistently outperformed Xerox Corporation (US) during the late 1970s.
  • FX net income became a vital component of Xerox consolidated earnings, often providing the cash flow necessary to offset US market losses.
  • Development costs for the FX 3500 were significantly lower than comparable US-led projects.
  • Xerox maintained a 50 percent equity stake but relied on FX for low-end copier manufacturing.

Operational Facts

  • FX transitioned from a sales-only organization to a full-scale R&D and manufacturing entity.
  • The FX 3500 model was developed independently in Japan and became the fastest-selling product in FX history.
  • Xerox US struggled with the 8200 and 9000 series, facing delays and reliability issues.
  • FX established a manufacturing lead time nearly 40 percent faster than US counterparts.

Stakeholder Positions

  • Tony Kobayashi, President of FX: Advocated for New Xerox Movement and increased autonomy from US management.
  • Xerox US Executives: Viewed FX as a subordinate entity intended to provide dividends and low-cost manufacturing.
  • Fuji Photo Film: Remained a passive partner but supported Kobayashi’s push for technological independence.
  • Xerox R&D (PARC and Webster): Resisted adopting Japanese-designed products due to Not Invented Here syndrome.

Information Gaps

  • Specific transfer pricing mechanisms between Xerox US and FX are not detailed.
  • The long-term capital expenditure budget for Xerox US R&D compared to FX is missing.
  • Detailed market share data for competitors like Canon and Ricoh in the European theater is absent.

Strategic Analysis

Core Strategic Question

  • The central dilemma is whether Xerox should maintain its colonial management structure or transition to a global partnership where FX leads product development for the low-to-mid market segments.

Structural Analysis

The Resource-Based View reveals a shift in core competencies. FX now possesses the superior manufacturing and incremental innovation capabilities required for the mid-market. Xerox US retains the high-end laser and software technology but lacks the operational discipline to compete on cost. The current 50/50 joint venture structure creates a bottleneck where US management vetoes Japanese innovations that the US market desperately requires.

Strategic Options

Option 1: Functional Integration. Reorganize Xerox into a global functional entity where FX is the global lead for all mid-range products. This requires Xerox US to cede R&D authority for these segments.
Trade-off: High political resistance in the US but immediate improvement in product competitiveness.

Option 2: Strategic Autonomy. Allow FX to operate as an independent competitor in certain neutral markets while maintaining the JV.
Trade-off: Potential for internal competition and brand dilution.

Preliminary Recommendation

Xerox must adopt Option 1. The company cannot afford to duplicate R&D costs. FX has proven its ability to develop reliable products faster and cheaper. Xerox US should focus exclusively on high-end systems and digital integration, leaving the hardware core of the mid-market to FX.

Implementation Roadmap

Critical Path

  • Month 1: Establish a Joint Global Product Planning Committee with equal voting rights.
  • Month 3: Transfer all mid-range hardware R&D leadership to FX headquarters in Japan.
  • Month 6: Standardize components across US and Japanese manufacturing sites to capture scale.

Key Constraints

  • Organizational Culture: The Not Invented Here bias at Xerox Webster will likely sabotage the adoption of FX designs.
  • Financial Dependence: Xerox US needs FX dividends to fund its own transformation, limiting its ability to reinvest in FX capacity.

Risk-Adjusted Implementation Strategy

The plan assumes FX can scale its R&D to meet global demand. To mitigate this, the transition will occur in phases, starting with the 3500 series rollout in North America. If quality metrics hold for six months, the full transfer of R&D authority will proceed.

Executive Review and BLUF

BLUF

Xerox is losing its competitive edge because it treats its most capable unit, Fuji Xerox, as a subordinate rather than a lead partner. To survive the onslaught from Canon and Ricoh, Xerox must immediately transfer global R&D and manufacturing authority for all mid-range copiers to FX. The US organization must pivot to software and high-end systems. Failure to cede control will result in a total collapse of the mid-market share within three years.

Dangerous Assumption

The most dangerous premise is that Xerox US can regain manufacturing competitiveness through internal cost-cutting. The structural cost gap between US and Japanese operations is too wide to bridge through incremental improvements.

Unaddressed Risks

  • Currency Risk: A significant shift in the Yen-Dollar exchange rate could erase the cost advantage of FX-manufactured goods overnight.
  • IP Leakage: Increasing FX autonomy may lead to Fuji Photo Film gaining access to sensitive Xerox digital technology, potentially creating a future competitor.

Unconsidered Alternative

The team failed to consider a full buyout of Fuji Photo Film stake in the JV. While capital-intensive, this would eliminate the governance friction and allow for a truly unified global strategy without the complexities of a 50/50 partnership.

Verdict

APPROVED FOR LEADERSHIP REVIEW


ALDI's Playbook for Retail Success custom case study solution

How Much Does an Opera Cost: Simon Boccanegra and the Bel Canto Opera custom case study solution

Scoring Talent: Global Soccer and the Independiente del Valle Model custom case study solution

Membertou First Nation: Possible Acquisition of Clearwater Seafoods custom case study solution

Sobha Group Real Estate: Backward Integration for Quality custom case study solution

Storehouse Tea: Cultivating Options for Growth custom case study solution

Transparency and Ethics at Everlane custom case study solution

Ipsen: Accelerating profitable growth in pharma custom case study solution

Chipotle: Capital Structure Decision custom case study solution

How Many Bottom Lines is One Life Worth? custom case study solution

eBay, Inc. custom case study solution

Patricia Coulter's Dilemma (A) custom case study solution

Mountainarious Sporting Co. custom case study solution

Best Financial Services Inc. custom case study solution

The Leader Project - Canada (A) custom case study solution